Comparative Pharmacology
Head-to-head clinical analysis: SULFAIR FORTE versus SULFAIR 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAIR FORTE versus SULFAIR 15.
SULFAIR FORTE vs SULFAIR-15
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Folate antagonist; inhibits dihydropteroate synthetase in bacterial folate synthesis pathway.
Sulfadoxine is a long-acting sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. Pyrimethamine inhibits dihydrofolate reductase, synergistically inhibiting nucleic acid synthesis in Plasmodium species.
Urinary tract infectionsAcute otitis mediaChronic bronchitisTraveler's diarrheaPneumocystis jirovecii pneumonia prophylaxis
FDA-approved for malaria prophylaxis and treatment of chloroquine-resistant Plasmodium falciparum malariaOff-label: treatment of toxoplasmosis (in combination with other agents)
1-2 tablets (sulfamethoxazole 400 mg/trimethoprim 80 mg per tablet) orally every 12 hours.
15 mg orally every 6 hours, not to exceed 60 mg/day.
None Documented
None Documented
Approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment (up to 20-30 hours), necessitating dose adjustment.
12–15 hours in healthy adults; prolonged to 20–30 hours in moderate hepatic impairment.
Hepatic metabolism via N-acetylation and glucuronidation.
Sulfadoxine is metabolized via acetylation and glucuronidation in the liver. Pyrimethamine is metabolized in the liver by CYP2C9 and other pathways.
Primarily renal excretion of unchanged drug (approx. 70-80%) and glucuronide conjugates; biliary excretion accounts for less than 20%; fecal elimination minimal.
Renal excretion unchanged: 70%; hepatic metabolism to inactive metabolites: 20%; fecal excretion: 10%.
Approximately 90-95% bound to serum albumin and alpha-1-acid glycoprotein.
98% bound to albumin.
0.15-0.2 L/kg, indicating limited extravascular distribution; primarily confined to extracellular fluid.
0.15 L/kg, indicating limited extravascular distribution.
Oral: 85-90%; topical: negligible systemic absorption (<5%).
Oral: 85%; intramuscular: 100%.
GFR >30 mL/min: no adjustment; GFR 15-30 mL/min: 50% of standard dose every 12 hours; GFR <15 mL/min: contraindicated.
GFR ≥ 60 mL/min: no adjustment; GFR 30-59: 15 mg every 8 hours; GFR 15-29: 15 mg every 12 hours; GFR <15: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, monitor hepatic function; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
6-12 years: 1 tablet (400/80 mg) every 12 hours; >12 years: adult dose; <6 years: not recommended (suspension available for younger children: 8 mg/kg/day trimethoprim divided every 12 hours).
0.5 mg/kg orally every 6 hours, maximum 60 mg/day; not recommended under 1 year.
Monitor renal function; adjust dose based on GFR; avoid in patients with GFR <15 mL/min; increased risk of hyperkalemia with ACE inhibitors or potassium-sparing diuretics.
Initial dose 7.5 mg every 6 hours; titrate to response; monitor renal function.
Do not use in pregnant women at term or in nursing mothers because sulfonamides cross the placenta and are excreted in breast milk and may cause kernicterus.
Fatal hypersensitivity reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported. Contraindicated in patients with a history of sulfonamide hypersensitivity.
Folate deficiency; hemolytic anemia in G6PD deficiency; hypersensitivity reactions; photosensitivity; renal impairment.
Risk of severe cutaneous adverse reactions (SJS/TEN); bone marrow suppression (especially with prolonged use); folate deficiency; hypersensitivity reactions; hematologic monitoring recommended.
Hypersensitivity to sulfonamides or sulfonylureas; severe hepatic or renal impairment; porphyria; pregnancy at term and lactation.
Hypersensitivity to sulfonamides or pyrimethamine; severe hepatic or renal impairment; megaloblastic anemia due to folate deficiency; pregnancy (first trimester) and lactation (potential harm to infant).
Data Pending Review
Data Pending Review
Avoid alcohol during treatment and for 3 days after. Limit high-potassium foods (bananas, oranges, spinach, salt substitutes) if on ACE inhibitors or potassium-sparing diuretics. Avoid folic acid supplements unless prescribed. Increase fluid intake to prevent kidney stones.
Avoid alcohol; may cause disulfiram-like reaction (flushing, headache, nausea). Maintain consistent carbohydrate intake to prevent hypoglycemia. Grapefruit juice may alter drug metabolism; limit or avoid consumption. High-fiber foods can delay absorption; take medication with a meal.
First trimester: Sulfadiazine crosses placenta; theoretical risk of folate antagonism with neural tube defects. Second/third trimesters: Risk of kernicterus in neonate due to bilirubin displacement; avoid near term.
First trimester: Sulfamethoxazole/trimethoprim (SMX/TMP) is associated with increased risk of neural tube defects, cardiovascular malformations, and oral clefts. Second/third trimester: Risk of kernicterus due to bilirubin displacement; avoid near term.
Sulfadiazine excreted in breast milk; M/P ratio ~0.5-1.0. Avoid in infants with G6PD deficiency or hyperbilirubinemia. Use with caution.
SMX/TMP is excreted into breast milk. M/P ratio for sulfamethoxazole is approximately 0.5-0.7; for trimethoprim, 0.7-1.5. Monitor infant for jaundice, rash, and diarrhea. Avoid in breastfeeding infants with G6PD deficiency or hyperbilirubinemia.
Increased renal clearance in pregnancy may reduce serum levels; monitor clinical response. No routine dose adjustment required.
Dose adjustment generally not required for SMX/TMP in pregnancy, but consider increased clearance of trimethoprim in second/third trimester. No standard dose modification; use lowest effective dose and avoid in first trimester and near term.
Category C
Category C
Sulfair Forte is a combination of sulfamethoxazole and trimethoprim. Monitor for hypersensitivity reactions, especially in HIV patients. Adjust dose in renal impairment (CrCl <30 mL/min contraindicated). Avoid in G6PD deficiency due to hemolysis risk. Use with caution in elderly and those with folic acid deficiency. Drug interactions: warfarin (increased INR), methotrexate (toxicity), sulfonylureas (hypoglycemia).
Sulfair-15 is a sulfonylurea antidiabetic agent with a rapid onset of action; monitor for hypoglycemia, especially in elderly patients or those with renal impairment. Avoid use in G6PD deficiency as it may precipitate hemolytic anemia. Titrate dose slowly to minimize risk of hypoglycemia. Consider dose adjustment when used with other hypoglycemic agents or drugs that affect hepatic metabolism.
Complete full course even if you feel better.Take with a full glass of water to prevent crystalluria.Avoid sunlight/UV exposure; use sunscreen.Report rash, fever, sore throat, or unusual bleeding.Not for use in pregnancy (especially 3rd trimester) or breastfeeding.Avoid alcohol (may cause disulfiram-like reaction).Do not take if allergic to sulfa drugs or have severe kidney disease.
Take this medication exactly as prescribed, typically once daily with breakfast to reduce gastrointestinal upset.Monitor blood glucose regularly and recognize symptoms of hypoglycemia (sweating, shakiness, hunger, confusion).Do not skip meals, and maintain a consistent carbohydrate intake to prevent blood sugar fluctuations.Avoid alcohol consumption as it can increase the risk of hypoglycemia.Inform your healthcare provider if you develop rash, jaundice, or signs of infection (fever, sore throat).